Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 49411 results
Aeterna Zentaris, Orient EuroPharma sign exclusive license deal for Zoptrex in Taiwan and Southeast Asia
Aeterna Zentaris has signed an exclusive license agreement with Cyntec, an affiliate of OEP (“Cyntec”), for its lead anti-cancer compound, Zoptrex (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia (the “Territory”).
Contract Research & Services > Contract Services > News
GeoVax files investigational new drug application for HIV human clinical trial
GeoVax Labs has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the conduct of the next human clinical trial of GeoVax’s preventive HIV vaccine.
Contract Research & Services > Clinical Trials > News
Citius Pharmaceuticals discontinues Suprenza to focus on core assets
Citius Pharmaceuticals is discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss.
Drug Research > Drug Discovery & Development > News
BIND Therapeutics files motion for sale of assets after accepting stalking horse bid from Pfizer
BIND Therapeutics has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer for the purchase of the majority of BIND's assets.
Contract Research & Services > Contract Services > News
Allergan gets positive opinion from Swedish MPA for Belkyra to treat patients with submental fullness
By PBR Staff Writer
Allergan has received a positive opinion from the Swedish Medical Products Agency (MPA) for Belkyra to treat patients with submental fullness.
Drug Research > Drug Delivery > News
UK’s NICE recommends Ferring’s Firmagon for men with advanced hormone-dependent prostate cancer
By PBR Staff Writer
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Ferring Pharmaceuticals’ Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases.
Production & Manufacturing > Process & Production > News
New Long-Range Wireless Technologies and User Interface Advances Are Changing Environmental Monitoring Applications
In this Q&A Janice Livingston, Vaisala's Life Science Managing Marketer, joins colleague and Senior Product Manager Jon Aldous, as he discusses a new environmental monitoring system created from new wireless technology.
News
EC grants orphan drug status to Mereo's BPS-804 for osteogenesis imperfecta
By PBR Staff Writer
Mereo BioPharma Group announced that its drug BPS-804 has been granted orphan drug designation by the European Commission (EC) in the treatment of osteogenesis imperfecta (OI).
Production & Manufacturing > Process & Production > News
Moberg Pharma agrees to acquire three US OTC brands from Prestige Brands
Moberg Pharma has signed an agreement to acquire New Skin, Fiber Choice and PediaCare, three well-established Over-The-Counter brands in the U.S. from Prestige Brands.
Production & Manufacturing > OTC > News
GSK starts phase I oncology study with ICOS agonist antibody
By PBR Staff Writer
GSK has started a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody.
Contract Research & Services > Clinical Trials > News
Shire’s retinopathy treatment fails to meet primary endpoint in phase 2 trial
By PBR Staff Writer
A phase 2 clinical trial assessing Shire’s investigational protein replacement, SHP607, failed to meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition.
Contract Research & Services > Clinical Trials > News
BMS, PsiOxus Therapeutics to study immuno-oncology combination
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and UK-based PsiOxus Therapeutics have agreed to work together on a new combination therapy targeting various tumor types in late-stage cancer patients.
Contract Research & Services > Contract Research > News
FDA declines to approve Lipocine’s LPCN 1021 testosterone drug
By PBR Staff Writer
The US Food and Drug Administration (FDA) has declined to approve Lipocine’s LPCN 1021 testosterone drug.
Regulatory Affairs > News
Xcovery starts phase 3 trial of X-396 in ALK+ non-small cell lung cancer
Xcovery has started its Phase 3 trial of X-396 in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Clinigen, Horizon Pharma partner to start European Managed Access program for RAVICTI Oral Liquid
Clinigen Group's Idis Managed Access (MA) division and Horizon Pharma have initiated a Managed Access program in Europe for Horizon’s RAVICTI (glycerol phenylbuterate) Oral Liquid.
Contract Research & Services > Contract Services > News
136-150 of 49411 results